Close Menu

NEW YORK (360Dx) – Bio-Techne announced after the close of the market on Monday that it has reached an agreement to acquire Exosome Diagnostics for up to $575 million.

Under the terms of the deal, expected to close in July or early August, Bio-Techne will pay $250 million in cash up front, and up to an additional $325 million contingent on the achievement of certain future milestones. The company said it will finance the deal through a combination of cash on hand and a revolving line of credit facility it anticipates obtaining prior to the closing of the deal.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.